NIH, Fox Foun­da­tion al­lies with bio­phar­mas on $24M Parkin­son's project; FDA ac­cepts Ther­a­vance/My­lan NDA for COPD drug

→ The NIH is team­ing up with The Michael J. Fox Foun­da­tion and a group of life sci­ences com­pa­nies on a $24 mil­lion ini­tia­tive to de­vel­op new bio­mark­ers for the pro­gres­sion of Parkin­son’s dis­ease. “These tech­nolo­gies could al­low us to tease out mi­cro­scop­ic dif­fer­ences in peo­ple with Parkin­son’s, which we may use to de­vel­op ob­jec­tive mea­sures of the dis­ease and treat­ments to slow or stop the Parkin­son’s process,” said MJFF CEO Todd Sher­er. “Lever­ag­ing ex­ist­ing stud­ies and part­ner­ing with the NIH and in­dus­try can move us faster to­ward these goals.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER